<DOC>
	<DOCNO>NCT02407314</DOCNO>
	<brief_summary>This interventional study assess effectiveness Ticagrelor reduction thrombus burden use optical coherence tomography patient undergoing peripheral artery stenting .</brief_summary>
	<brief_title>Ticagrelor Peripheral Arterial Disease</brief_title>
	<detailed_description>Prospective , randomize study , compare ticagrelor + aspirin vs. aspirin monotherapy follow 4-week post-procedural combination Ticagrelor Plavix low dose aspirin . The investigator enroll minimum 40 patient . Patients enrol either claudication and/or critical limb ischemia , angiographically identify superficial femoral artery ( SFA ) disease require intervention , either total occlusion significant SFA stenosis presence Optical Coherence Tomography ( OCT ) define clot follow stent placement . Participants evaluate baseline , 1 month , 4 month , 6 7 month follow SFA intervention . At baseline demographic data collect , anthropomorphic physiological variable ( body mass index , waist circumference , blood pressure ) . Baseline 6-month ankle brachial index ( ABI ) perform . A 6-min walk test perform baseline 6-month follow-up . At 6 month time point patient treatment group return peripheral angiogram repeat OCT image SFA segment interest . Subject final follow clinic visit 7 month .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients low extremity claudication PAD due significant SFA stenosis ( &gt; 60 % ) total occlusion ( Rutherford 26 ) affect quality life despite medical therapy . The presence OCT identify clot Superficial Femoral Artery ( SFA ) follow stent placement . Evidence significant SFA disease involve symptomatic limb establish noninvasive vascular testing ( anklebrachial index [ ABI ] &lt; 0.9 , toe brachial Index [ TBI ] &lt; 0.6 . If ABI &gt; 1.4 , SFA systolic acceleration time &gt; 140 millisecond ) ; compute tomographic angiography , magnetic resonance angiography confirm least 60 % stenosis SFA . At least one nontreated Below The Knee ( BTK ) vessel patent Male female outpatient 18 year age . The following device may use revascularization procedure : conventional balloon bare metal stent ( block randomization ) . Subject advise beneficial effect smoke cessation regular exercise must process change smoke status time screen . Patients may resume increase exercise effect post procedurally improve low limb perfusion . Peak Walking Time ( PWT ) limit claudication . Willingness participate , document write informed consent . Patients require dual antiplatelet drug treatment start study Planned amputation Use atherectomy device Hypersensitivity acetylsalicylic acid , ticagrelor . For ticagrelor , hypersensitivity reaction past include angioedema Patients know bleed disorder Patients know active pathological bleeding Patients need chronic oral anticoagulant maintenance therapy Patients history intracranial hemorrhage time , GI bleed past 6 month , major surgery within past 30 day Ischemic stroke past 3 month Patients consider risk bradycardic event unless treat permanent pacemaker Target restenotic lesion instent restenosis Any schedule revascularization procedure require dualantiplatelet therapy one month Severe hypertension may put patient risk , systolic great equal 180 and/or diastolic great equal 100 Severe liver disease History congestive heart failure Left Ventricular Ejection Fraction ( LVEF ) less 30 % Concern inability patient comply study procedure and/or follow ( eg , alcohol drug abuse ) Infrapopliteal disease involve last remaining vessel ( single runoff ) Prior low extremity revascularization within past 30 day prior enrollment Atherectomy PAD EXCIPIENTS ticagrelor hypersensitivity Known pregnancy , breastfeeding , intend become pregnant study period ( female patient 55 year young , without past history hysterectomy must pregnancy test prior peripheral intervention baseline 6 month ) Creatinine clearance &lt; 30 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Optical Coherence Tomography</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Claudication</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>